Publications
98 results found
Kenny LM, Coombes RC, Al-Nahhas A, et al., 2006, A feasibility study of [(11)C]choline for the molecular imaging of human breast cancer in vivo using positron emission tomography (PET)., J Clin Oncol, Vol: 24
613 Background: [(11)C]Choline is a novel PET radiotracer. Preclinical studies suggest that it may be promising in breast cancer. [(11)C]Choline has been recently evaluated as a screening agent in prostate cancer, but no studies have yet investigated its potential in breast cancer. We report a pilot study evaluating the utility and reproducibility of [(11)C]Choline-PET in breast cancer. METHODS: Dynamic imaging was performed on an ECAT962 HR+ PET scanner for 65 min after intravenous injection with 190-369 MBq [(11)C]choline. Patients with locally advanced and metastatic breast cancer were eligible. All histological subtypes were included (ductal, lobular, and inflammatory). Arterial blood samples were taken continuously for 10 min, with 8 discrete samples up to 60 min to measure [(11)C]choline and metabolites. Tissue uptake was determined by standardised uptake value at 60 min (SUV, dose and BSA corrected) and Ki (irreversible trapping) calculated using Patlak (corrected for [(11)C]choline metabolites in plasma) and modified Patlak analysis (corrected for plasma + tissue metabolites). Reproduciblilty scans were performed 2-17 days later in the absence of treatment. RESULTS: Tumour [(11)C]choline uptake was observed in 10 out of 11 patients (12 out of 13 distinct lesions). There was a significant difference between tumour and normal tissue (breast/lung) in [(11)C]choline uptake for Ki (p<0.0001) and SUV (p<0.0001). Tissue uptake was of the order lung ≤ normal breast < tumour < liver ≤ spleen. [(11)C]choline was rapidly metabolised, at 60 min the mean ± S.E. plasma radioactivity due to [(11)C]choline was 16.4 ± 2.9%. [(11)C]Choline uptake was found to be reproducible for Ki (modified Patlak: r=0.93, p<0.0001, Patlak: r=0.85, p=0.002) and SUV (r=0.94, p<0.0001) - measured in 8 patients (median of 2 days after the 1(st) scan). Tumour Patlak Ki was 13.2% > Ki calculated using modified Patlak analysis. CONCLUSIONS: [(11)C]Choline-P
Kenny LM, Aboagye EO, Al-Nahhas A, et al., 2006, [<SUP>11</SUP>C]choline-PET in human breast cancer:: utility, reproducibility and effect of receptor tyrosine kinase inhibition by trastuzumab., 29th Annual San Antonio Breast Cancer Symposium, Publisher: SPRINGER, Pages: S212-S212, ISSN: 0167-6806
- Author Web Link
- Cite
- Citations: 1
Kenny LM, Vigushin DM, Al-Nahhas A, et al., 2005, Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [<SUP>18</SUP>F]fluorothymidine-positron emission tomography imaging:: Evaluation of analytical methods., CANCER RESEARCH, Vol: 65, Pages: 10104-10112, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 159
Kenny LM, Vigushin DM, Coombes RC, et al., 2005, Early assessment of response to treatment in breast cancer by [<SUP>18</SUP>F]fluorathymidine-positron emission tomography., 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Publisher: AMER SOC CLINICAL ONCOLOGY, Pages: 155S-155S, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 1
Kenny LM, Al-Nahhas A, Vigushin D, et al., 2004, [<SUP>18</SUP>F]Fluorothymidine retention in breast cancer measured by PET -: Initial results from a pilot study, 17th Annual Congress of the European-Association-of-Nuclear-Medicine, Publisher: SPRINGER, Pages: S328-S328, ISSN: 1619-7070
Kenny L, Al-Nahhas A, Shousha S, et al., 2004, Determination of [<SUP>18</SUP>F]fluorothymidine kinetics in tumour and normal tissues of patients with breast cancer using positron emission tomography., British Cancer Research Meeting 2004, Publisher: NATURE PUBLISHING GROUP, Pages: S44-S44, ISSN: 0007-0920
Kenny L, McAleer JJ, 2004, Elevated serum beta-hCG due to a tumour of unknown origin., Ulster Med J, Vol: 73, Pages: 47-49, ISSN: 0041-6193
Kenny LM, Aboagye E, Price P, 2004, Positron emission tomography imaging of cell proliferation in oncology, Clin Oncol, Vol: 16, Pages: 176-185
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.